The current and emerging state of noninvasive body contouring
April 21st 2020At the most recent ASDS meeting, Catherine DiGiorgio, M.D., Boston, discusses the current state of noninvasive body contouring, and what noninvasive devices and procedures will soon hit the market including a collagenase clostridium histolyticum injection and cellulite-targeting devices that use electromagnetic stimulation and radiofrequency.
LEO Pharma enters agreement to develop novel drug for atopic dermatitis, asthma
April 15th 2020LEO Pharma has entered into a license agreement with Oneness Biotech and Microbio Shanghai for the development and commercialization of the investigational drug FB825 for the treatment of atopic dermatitis and asthma.
The Mainstream Patient: April 14
April 14th 2020This week’s edition of The Mainstream Patient revolves around COVID-19, featuring articles about the effects of blue light on our skin, wearing sunscreen even while indoors, the integration of teledermatology and how the pandemic is affecting front line workers' skin.
Ixekizumab approved for pediatric plaque psoriasis
April 10th 2020Eli Lilly announces the U.S. Food and Drug Administration approval of ixekizumab (Taltz) for treatment of moderate-to-severe plaque psoriasis in pediatric patients 6 and under 18 who are also eligible for phototherapy and systemic therapy.
Red light treatment proves safe, effective for androgenetic alopecia
April 6th 2020REVIAN Inc. releases data from their investigational study examining their REVIAN RED dual wavelength LED light treatment for androgenetic alopecia, showing the FDA-cleared device to be both safe and effective at week 16 in a 26-week trial.
Combination therapy significantly improves rosacea symptoms
February 19th 2020A combination of ivermectin 1% cream and oral 40-mg doxycycline has the potential to be an effective therapy for some people with moderate to severe rosacea after the publication of results from a phase 3b/4 study examining the combination’s efficacy and safety compared to ivermectin as a monotherapy.
Oral JAK inhibitor appears safe, effective for atopic dermatitis
February 17th 2020Eli Lilly and Incyte announces positive results of two phase 3 clinical trials investigating the use of JAK inhibitor baricitinib as both a monotherapy and combination therapy for moderate-to-severe atopic dermatitis.